Biotalys develops a new generation of protein-based biocontrol solutions built on a proprietary technology platform, aiming to combine chemical-like performance with the safety profile of biologicals. The company has a broad pipeline addressing crop pests and diseases across the value chain, and its lead biofungicide, BioFun-1, has shown consistent high efficacy in global fruit and vegetable trials. Biotalys was on track in 2020 to submit BioFun-1 registration dossiers later that year and expected a U.S. launch in 2022 followed by global introductions. The firm is advancing a protein-based bio-bactericide program targeting bacterial diseases including cankers, blight and spots. Financially, Biotalys has raised €61 million ($66m USD) to date from specialist international investors and supplements that financing with non-dilutive research grants. The company was founded in 2013 as a VIB spin-off and is based in Ghent, Belgium. Biotalys is developing a new generation of protein-based biocontrols intended to provide high-performance crop protection with the safety profile of biologicals. Its technology platform has produced a pipeline of products with novel modes of action addressing pests and diseases across the value chain, from soil to plate. The company positions its protein-based solutions for both pre- and post-harvest applications, aiming to combine chemical-like consistency with biological safety. Proceeds from the Series C will fund development, regulatory registration and commercial-scale production of its lead biofungicide and further expansion of the discovery platform. Biotalys plans to launch its first biofungicide in 2022 in the U.S. fruit and vegetables market and to accelerate development of its broader pipeline. Founded in 2013 as a spin-off from VIB, the company is based in Ghent, Belgium and had raised €61 million to date. AgroSavfe is developing a new generation of protein-based biocontrols based on its proprietary AGROBODY™ Foundry Platform to protect seeds, crops and food from farm to fork. Its product candidates include biofungicide and bioinsecticide candidates that the company says combine chemical-like performance with the clean safety profile of biologicals and leave no residues. The company reports more than 100 field trials since 2017, with its most advanced biofungicide demonstrating strong, competitive performance versus synthetic chemicals. Planned uses include pre- and post-harvest applications to reduce food loss and improve food quality along the value chain. The company intends to use recent funding to support development, registration and commercial-scale production of its biofungicide and bioinsecticide products and to strengthen its organization. AgroSavfe scheduled the launch of its first biofungicide for 2022 in the U.S. fruit and vegetables market, followed by launches in Europe and other regions. AgroSavfe is a Ghent, Belgium-based agro-biotech spin-off from VIB that develops Agrobodies, small proteins designed and formulated to specifically bind to essential target molecules of crop pests and diseases. The company is led by Managing Director Marnix Peferoen. Agrobodies are positioned as a new generation of biopesticides and are the firm's core product. AgroSavfe extended its Series B financing round to €11m. The company intends to use the funds to accelerate development of its Agrobodies and to roll out the international registration process. Earlier investors include Agri Investment Fund, Biovest, Gimv, Globachem, Madeli Participaties, PMV, Qbic and VIB, with Sofinnova Partners joining the extension. AgroSavfe is a Gent, Belgium-based green biotech spin-off of the VIB department of the Free University of Brussels. The company develops innovative formulations of crop protection products using its proprietary Agrobody technology. It will focus on research and development of those formulations. Led by CEO Marnix Peferoen, AgroSavfe is based in the VIB Bio-incubator in the Ghent technology park and employs nine people. The company raised €5m in funding to support its activities. The articles do not disclose revenue, prior rounds, or whether the funding was equity or debt.

Total raised

$70M

Funding rounds

5

Latest round

Grant

Latest activity

Oct 2020